HeartBeam (BEATW) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Cash Used in Operating Activities: $3.3 million, a 7% decrease from Q1 2026 and a 3% decrease from Q2 2025.

Net Loss: $5 million for the quarter, with underlying loss adjusted to approximately $4.1 million after accounting for one-time items related to leadership transition.

Cash Position: As of June 30, 2026, cash equivalents and restricted cash totaled $8.8 million. The company expects to maintain a reduced operating cash outflow of below $2.5 million per quarter starting in Q4 2026.

2Strategic Updates and Business Highlights

Product Development: Completed prototypes for both the credit card-sized device and the 12-lead patch, which are designed for heart attack detection and monitoring.

Clinical Studies: Rapid enrollment in pilot studies for heart attack detection, with positive results expected to be presented at the TCT conference. The ALIGN-ACS study was completed in under four months.

FDA Submission: A pre-submission for heart attack detection was submitted, with expectations for a pivotal trial to begin by year-end.

Commercial Launch: Initial commercial rollout is underway, focusing on concierge practices in key U.S. markets (New York, Dallas, South Florida, Southern California), with early positive feedback from physicians and patients.

Integrated Network Partnerships: Engaging with large healthcare networks to incorporate HeartBeam technology into their workflows, particularly in emergency and post-procedure settings.

3Forward Guidance and Outlook

Revenue Generation: The company anticipates revenue growth in the second half of 2026 as commercial deployments ramp up.

Patient Onboarding: Targeting approximately 30,000 patients to reach cash flow positivity, with a large potential patient pool in concierge practices.

Cost Management: Continued focus on operational efficiencies and cost reductions, with expectations to extend cash runway into 2027.

4Bad News, Challenges, or Points of Concern

Net Loss: The company reported a significant net loss, which, while in line with expectations, highlights ongoing financial challenges.

Leadership Transition Costs: One-time expenses related to the leadership transition have impacted net loss figures.

Market Competition: The company faces competition in the medical device space, particularly in cardiac monitoring, which could affect market penetration and pricing strategies.

5Notable Q&A Insights

Licensing Strategy: Clarified that the focus is on partnerships rather than traditional licensing, particularly with integrated healthcare systems.

International Expansion: Currently prioritizing the Indonesian market for trials, with plans to evaluate other international opportunities based on outcomes.

Concierge Market Potential: Approximately 1.9 million patients are embedded in concierge practices, with a significant portion likely to be at-risk cardiac patients.

Commercial Rollout Insights: Early learnings indicate the importance of streamlining workflows in concierge practices to facilitate faster adoption of HeartBeam technology. Overall, HeartBeam is positioned to leverage its innovative technology in cardiac monitoring, with a clear path toward commercialization and regulatory approval, despite facing financial losses and competitive pressures.